Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells

References

• Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 376:245–251.
   PubMed Web of Science ®Google Scholar
• Ballangrud AM, Yang WH, Dnistrian A, Lampen NM, Sgouros G. 1999. Growth and characterization of LNCaP prostate cancer cell spheroids. Clin Cancer Res. 5:3171s–3176s.
   PubMed Web of Science ®Google Scholar
• Bendell J, O’Reilly EM, Middleton MR, Chau I, Hochster H, Fielding A, Burke W, Burris H 3rd. 2015. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. Ann Oncol. 26:804–811.
   PubMed Web of Science ®Google Scholar
• Blackman RK, Cheung-Ong K, Gebbia M, Proia DA, He S, Kepros J, Jonneaux A, Marchetti P, Kluza J, Rao PE, et al. 2012. Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS One. 7:e29798.
   PubMed Web of Science ®Google Scholar
• Bonkhoff H. 2012. Factors implicated in radiation therapy failure and radiosensitization of prostate cancer. Prostate Cancer. 2012:593241.
   PubMedGoogle Scholar
• Brock WA, Milas L, Bergh S, Lo R, Szabó C, Mason KA. 2004. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. 205:155–160.
   PubMed Web of Science ®Google Scholar
• Bull EEA, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ. 2004. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res. 10:8077–8084.
   PubMed Web of Science ®Google Scholar
• Butler LM, Ferraldeschi R, Armstrong HK, Centenera MM, Workman P. 2015. Maximizing the therapeutic potential of HSP90 inhibitors. Mol Cancer Res. 13:1445–1451.
   PubMed Web of Science ®Google Scholar
• Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, et al. 2004. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 96:56–67.
   PubMed Web of Science ®Google Scholar
• Carroll AG, Voeller HJ, Sugars L, Gelmann EP. 1993. p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 23:123–134.
   PubMed Web of Science ®Google Scholar
• Chalmers AJ. 2009. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull. 89:23–40.
   PubMed Web of Science ®Google Scholar
• Den RB, Lu B. 2012. Heat shock protein 90 inhibition: rationale and clinical potential. Ther Adv Med Oncol. 4:211–218.
   PubMed Web of Science ®Google Scholar
• Dote H, Burgan WE, Camphausen K, Tofilon PJ. 2006. Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res. 66:9211–9220.
   PubMed Web of Science ®Google Scholar
• Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, et al. 2016. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer 114:723–730.
   PubMed Web of Science ®Google Scholar
• Enmon R, Yang WH, Ballangrud AM, Solit DB, Heller G, Rosen N, Scher HI, Sgouros G. 2003. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res. 63:8393–8399.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434:917–921.
   PubMed Web of Science ®Google Scholar
• Harashima K, Akimoto T, Nonaka T, Tsuzuki K, Mitsuhashi N, Nakano T. 2005. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor. Int J Radiat Biol. 81:63–76.
   PubMed Web of Science ®Google Scholar
• Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA. 2005. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol. 56:115–125.
   PubMed Web of Science ®Google Scholar
• Horton JK, Stefanick DF, Prasad R, Gassman NR, Kedar PS, Wilson SH. 2014. Base excision repair defects invoke hypersensitivity to PARP inhibition. Mol Cancer Res. 12:1128–1139.
   PubMed Web of Science ®Google Scholar
• Kirshner JR, He S, Belasubramanyam Z, Kepros J, Yang CY, Zhang M, Du Z, Barsoum J, Bertin J. 2000. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther. 7:2319–2327.
   Web of Science ®Google Scholar
• Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, Bradsher J, Capala J, Varticovski L. 2008. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther. 7:1985–1992.
   PubMed Web of Science ®Google Scholar
• Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. 2008. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 68:1777–1785.
   PubMed Web of Science ®Google Scholar
• Kwok TT, Twentyman PR. 1985. The relationship between tumour geometry and the response of tumour cells to cytotoxic drugs-an in vitro study using EMT6 multicellular spheroids. Int J Cancer. 35:675–682.
   PubMed Web of Science ®Google Scholar
• Lu X, Xiao L, Wang L, Ruden DM. 2012. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem Pharmacol. 83:995–1004.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. 2009. Targeting HSP90 for cancer therapy. Br J Cancer. 100:1523–1529.
   PubMed Web of Science ®Google Scholar
• Mairs RJ, Boyd M. 2011. Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors. Semin Nucl Med. 41:334–344.
   PubMed Web of Science ®Google Scholar
• Mangerich A, Burkle A. 2011. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation. Int J Cancer. 128:251–265.
   PubMed Web of Science ®Google Scholar
• Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, et al. 2015. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 373:1697–1708.
   PubMed Web of Science ®Google Scholar
• Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63.
   PubMed Web of Science ®Google Scholar
• Nagai M, Vo NH, Shin Ogawa L, Chimmanamada D, Inoue T, Chu J, Beaudette-Zlatanova BC, Lu R, Blackman RK, Barsoum J, et al. 2012. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic Biol Med. 52:2142–2150.
   PubMed Web of Science ®Google Scholar
• Neshasteh-Riz A, Angerson WJ, Reeves JR, Smith G, Rampling R, Mairs RJ. 1997. Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters. Br J Cancer. 75:493–499.
   PubMed Web of Science ®Google Scholar
• O’Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, Haddad J, Kong S, Williams A, Jacobson E. 2009. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 27:5452–5458.
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, et al. 2013. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 31:1211–1218.
   PubMed Web of Science ®Google Scholar
• Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, et al. 2011. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res. 17:1561–1570.
   PubMed Web of Science ®Google Scholar
• Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, et al. 2013. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol. 71:1191–1199.
   PubMed Web of Science ®Google Scholar
• Qu Y, Wang J, Sim MS, Liu B, Giuliano A, Barsoum J, Cui X. 2009. Elesclomol, counteracted by Akt survival signalling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells. Breast Cancer Res Treat. 121:311–321.
   PubMed Web of Science ®Google Scholar
• Rae C, Haberkorn U, Babich JW, Mairs RJ. 2015. Inhibition of fatty acid synthase sensitizes prostate cancer cells to radiotherapy. Radiat Res. 184:482–493.
   PubMed Web of Science ®Google Scholar
• Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ. 2003. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res. 9:3749–3755.
   PubMed Web of Science ®Google Scholar
• Solit DB, Chiosis G. 2008. Development and application of Hsp90 inhibitors. Drug Discov Today. 13:38–43.
   PubMed Web of Science ®Google Scholar
• Soo ET, Yip GW, Lwin ZM, Kumar SD, Bay BH. 2008. Heat shock proteins as novel therapeutic targets in cancer. In Vivo 22:311–315.
   PubMed Web of Science ®Google Scholar
• Storz P. Reactive oxygen species in tumor progression. 2005 Front Biosci. 10:1881–1896.
   PubMed Web of Science ®Google Scholar
• Tesson M, Rae C, Nixon C, Babich JW, Mairs RJ. 2016. Preliminary evaluation of prostate-targeted radiotherapy using 131I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs. J Pharm Pharmacol. 68:912–921.
   PubMed Web of Science ®Google Scholar
• Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV, Myles DC. 2004. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem. 12:5317–5329.
   PubMed Web of Science ®Google Scholar
• Trachootham D, Alexandre J, Huang P. 2009. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 8:579–591.
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 376:235–244.
   PubMed Web of Science ®Google Scholar
• Verheij M, Vens C, van Triest B. 2010. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist Updat. 13:29–43.
   PubMed Web of Science ®Google Scholar
• Virag L, Szabo C. 2002. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 54:375–429.
   PubMed Web of Science ®Google Scholar
• Wittgen HG, van Kempen LC. 2007. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res. 17:400–409.
   PubMed Web of Science ®Google Scholar
• Xie BX, Zhang H, Yu L, Wang J, Pang B, Wu RQ, Qian XL, Li SH, Shi QG, Wang LL, Zhou JG. 2010.The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP. Asian J Androl. 12:405–414.
   PubMed Web of Science ®Google Scholar
• Yamamori T, Yasui H, Yamazumi M, Wada Y, Nakamura Y, Nakamura H, Inanami O. 2012. Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint. Free Radic Biol Med. 53:260–270.
   PubMed Web of Science ®Google Scholar
• Yossepowitch O, Pinchuk I, Gur U, Neumann A, Lichtenberg D, Baniel J. 2007. Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol. 178:1238–1243.
   PubMed Web of Science ®Google Scholar
• Yuhas JM, Li AP, Martinez AO, Landman AJ. 1977. A simplified method for production and growth of multicellular tumor spheroids. Cancer Res. 37:3639–3643.
   PubMed Web of Science ®Google Scholar
• Zaremba T, Ketzer P, Cole M, Coulthard S, Plummer ER, Curtin NJ. 2009. Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br J Cancer. 101:256–262.
   PubMed Web of Science ®Google Scholar